🇺🇸 FDA
Patent

US 11406643

Targeting kinases for the treatment of cancer metastasis

granted A61KA61K31/133A61K31/137

Quick answer

US patent 11406643 (Targeting kinases for the treatment of cancer metastasis) held by The Board of Regents of the University of Texas System expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K31/133, A61K31/137, A61K31/18, A61K31/352